乌鸦传媒

More evidence linking talc-containing and other to an increased risk of ovarian cancers. (Journal of Clinical Oncology)

Bristol Myers Squibb (BMS) announced FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi) for adults with previously treated, .

BMS also announced that a phase III trial in showed no improvement in progression-free survival with nivolumab (Opdivo) plus concurrent chemoradiation (CCRT) followed by nivolumab and ipilimumab (Yervoy) versus CCRT and durvalumab (Imfinzi).

Increased rates of tanning and burning have put Gen Z adults (18-25) at greater , according to a survey by the American Academy of Dermatology.

The FDA has once again turned down a , this time camrelizumab and the VEGFR inhibitor rivoceranib as combination therapy for liver cancer. (Fierce Pharma)

More evidence that a diet heavy in fruits and vegetables and light on animal products can reduce the risk of progression. (University of California San Francisco, JAMA Network Open)

The popularity of continues to increase, particularly in patients younger than 50. (Epic Research)

more than doubled when patients were given the option of a take-home test kit or colonoscopy, as compared with only colonoscopy. (Penn Medicine, Clinical Gastroenterology and Hepatology)

A combination of the estrogen receptor degrader vepdegestrant and the CDK4/6 inhibitor palbociclib (Ibrance) led to objective responses in 41.9% of patients with heavily pretreated , Arvinas and Pfizer announced.

Ultrasound may offer an for detecting cancer biomarkers. (Acoustical Society of America, University of Alberta)

MacroGenics disclosed during an investor call that five patients have died during an ongoing clinical trial of the company's antibody-drug conjugate vobramitamab duocarmazine. (BioSpace)

did not improve survival for patients with advanced solid tumors. (JAMA Oncology)

Comment